Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered oral for the treatment of steatohepatitis associated with metabolic dysfunction
(MASH), or NASH, and other diseases with unmet medical need, today announces positive interim results from its LEGEND proof-of-concept clinical trial evaluating lanifibranor in combination with empagliflozin in patients with MASH/NASH and poorly controlled type 2 diabetes (T2DM).